SCHEMBL25486202

SCHEMBL25486202

CCn1ccc(C(=O)Nc2cnc(OC)c(S(=O)(=O)Nc3c(C)cccc3C)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.53
ALDH1A1 P00352 3/20 0.53
LMNA P02545 2/20 0.53
MAPK1 P28482 1/20 0.53
RAB9A P51151 8/20 0.49
NPC1 O15118 7/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.42
APLNR P35414 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 2/20 0.39
APOBEC3G Q9HC16 1/20 0.39
ROCK1 Q13464 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
PIK3C3 Q8NEB9 1/20 0.37
GRM4 Q14833 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23840352 0.91 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1LMNAMAPK1RAB9A
SCHEMBL23840380 0.88 MEN1 (0.54) SMN1; SMN2ALDH1A1LMNAMAPK1RAB9A
SCHEMBL23840408 0.86 AURKA (0.52) SMN1; SMN2ALDH1A1LMNAMAPK1MEN1
SCHEMBL25485963 0.86 MEN1 (0.40) SMN1; SMN2ALDH1A1LMNAMAPK1RAB9A
SCHEMBL23840321 0.84 MEN1 (0.39) SMN1; SMN2ALDH1A1LMNAMAPK1RAB9A
SCHEMBL23840413 0.84 LMNA (0.48) SMN1; SMN2ALDH1A1LMNAMAPK1GAA
SCHEMBL23840501 0.83 MEN1 (0.43) SMN1; SMN2ALDH1A1LMNAMAPK1RAB9A
SCHEMBL23840341 0.83 KMT2A (0.46) SMN1; SMN2ALDH1A1LMNARAB9ANPC1
SCHEMBL25486018 0.82 KDR (0.40) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL23840415 0.82 MEN1 (0.45) SMN1; SMN2ALDH1A1LMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D SMN1; SMN2 428/4885ALDH1A1 2592/4885LMNA 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.